NC
CORT icon

Nexthera Capital’s Corcept Therapeutics CORT Stock Holding History

Nexthera Capital’s Portfolio CORT Stock Details CORT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-335,177
Closed -$5.27M – 58
2018
Q2 		$5.27M Sell
335,177
-710,019
-68% -$12.4M 0.82% 28
2018
Q1 		$17.2M Buy
+1,045,196
New +$19.4M 2.83% 8

Other funds holding CORT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ISL
Ingalls & Snyder LLC New York $2.83B AUM 21.61% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Nexthera Capital's CORT Position: Q3 2018 in Review

Nexthera Capital sold out of Corcept Therapeutics (CORT) in Q3 2018, closing a stake of 335,177 shares — an estimated $5.27M sold.

Nexthera Capital first reported a position in CORT in Q1 2018 and held it in 2 quarters. The position peaked at $17.2M in Q1 2018. 207 funds tracked by Wall St. Rank hold CORT as of Q3 2018.

  • Nexthera Capital reported no remaining Corcept Therapeutics position as of Q3 2018 after selling out during the quarter.
  • Nexthera Capital sold 335,177 Corcept Therapeutics shares in Q3 2018, an estimated $5.27M.
  • Nexthera Capital first reported a position in Corcept Therapeutics in Q1 2018 and held it in 2 quarters.
  • Nexthera Capital's Corcept Therapeutics position peaked at $17.2M in Q1 2018.
  • 207 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q3 2018.

Based on Nexthera Capital's 13F filing for Q3 2018, filed 14 Nov 2018.